Black Rock Inc. Arca Biopharma, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Arca Biopharma, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 247,909 shares of ABIO stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

247,909

Previous 231,238 7.21%

Holding current value

Previous $406,000 133.74%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.71 - $4.0 $28,507 - $66,684	16,671 Added 7.21%	247,909 $949,000
Q1 2024 May 10, 2024	SELL	$1.58 - $1.78 $1,063 - $1,197	-673 Reduced 0.29%	231,238 $406,000
Q4 2023 Feb 13, 2024	SELL	$1.7 - $2.05 $81 - $98	-48 Reduced 0.02%	231,911 $394,000
Q2 2023 Aug 11, 2023	SELL	$1.94 - $2.11 $63,577 - $69,148	-32,772 Reduced 12.38%	231,959 $470,000
Q1 2023 May 12, 2023	BUY	$1.99 - $2.55 $2,089 - $2,677	1,050 Added 0.4%	264,731 $526,000
Q4 2022 Feb 13, 2023	BUY	$1.86 - $25.8 $472 - $6,553	254 Added 0.1%	263,681 $624,000
Q3 2022 Nov 14, 2022	SELL	$2.13 - $25.68 $1,863 - $22,470	-875 Reduced 0.33%	263,427 $542,000
Q2 2022 Aug 12, 2022	SELL	$2.2 - $2.53 $12,265 - $14,104	-5,575 Reduced 2.07%	264,302 $658,000
Q1 2022 May 12, 2022	SELL	$1.77 - $2.49 $3,265 - $4,594	-1,845 Reduced 0.68%	269,877 $620,000
Q4 2021 Feb 10, 2022	BUY	$2.15 - $2.97 $7,155 - $9,884	3,328 Added 1.24%	271,722 $585,000
Q3 2021 Nov 09, 2021	SELL	$2.77 - $3.74 $13,982 - $18,879	-5,048 Reduced 1.85%	268,394 $795,000
Q2 2021 Aug 11, 2021	BUY	$3.06 - $3.9 $836,732 - $1.07 Million	273,442 New	273,442 $954,000

Others Institutions Holding ABIO

# of Institutions

Shares Held

280K

Call Options Held

Put Options Held

Tekla Capital Management LLC

32.5K
Shares

$0
0.0% of portfolio

View Full List

About ARCA biopharma, Inc.

Ticker ABIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,410,100
Description
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydr...

More about ABIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account